PCYC-04753: BTK Inhibitor Phase I Trial in B-cell Lymphoma

      To access the most up-to-date information on this study,
      please refer to this page at ClinicalTrials.gov.

Official Title

Phase I Dose-Escalation Study of Bruton ‘s Tyrosine Kinase (BTK) Inhibitor PCI-32765 in Recurrent B-cell lymphoma

Purpose

The purpose of this study is to determine the highest dose of PCI-32765 that can be taken by month in oral capsule form without causing serious side effects in patients with recurrent B-cell lymphoma. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.